These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ Ann Emerg Med; 1998 Dec; 32(6):712-22. PubMed ID: 9832669 [TBL] [Abstract][Full Text] [Related]
11. Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ Eur J Emerg Med; 1998 Dec; 5(4):391-402. PubMed ID: 9919443 [TBL] [Abstract][Full Text] [Related]
12. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. Januzzi JL; Sabatine MS; Wan Y; Servoss SJ; DiBattiste PM; Jang Ik; Theroux P Am J Cardiol; 2003 Feb; 91(4):457-61. PubMed ID: 12586266 [No Abstract] [Full Text] [Related]
13. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. Shimpi RA J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880 [No Abstract] [Full Text] [Related]
14. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139 [TBL] [Abstract][Full Text] [Related]
15. Facilitated percutaneous coronary intervention: a novel concept in expediting and improving acute myocardial infarction care. Li RH; Herrmann HC Am Heart J; 2000 Dec; 140(6 Suppl):S125-35. PubMed ID: 11100006 [No Abstract] [Full Text] [Related]
16. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW; Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770 [TBL] [Abstract][Full Text] [Related]
17. The dark side of platelet glycoprotein IIb/IIIa receptor inhibitors during percutaneous coronary interventions. Klein LW; Calvin JE Am J Cardiol; 2003 May; 91(10):1199-202. PubMed ID: 12745103 [No Abstract] [Full Text] [Related]
18. Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Welsford M; Nikolaou NI; Beygui F; Bossaert L; Ghaemmaghami C; Nonogi H; O'Connor RE; Pichel DR; Scott T; Walters DL; Woolfrey KG; Circulation; 2015 Oct; 132(16 Suppl 1):S146-76. PubMed ID: 26472852 [No Abstract] [Full Text] [Related]
19. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target? Topaz O Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986 [No Abstract] [Full Text] [Related]
20. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects. Reginelli JP; Topol EJ Am J Med; 2000 Aug; 109(3):252-4. PubMed ID: 10974193 [No Abstract] [Full Text] [Related] [Next] [New Search]